The plasma level of soluble VCAM1 (sVCAM1), which acts as a decoy receptor that inhibits VCAM1-mediated signaling, was 34% higher in patients with AD than in healthy controls (Fig. 6a). This evidence concerns the gene VCAM1 and Alzheimer disease.